<DOC>
	<DOCNO>NCT00490529</DOCNO>
	<brief_summary>Mantle Cell Lymphoma sub-type Non-Hodgkin 's Lymphoma generally consider incurable current therapy . Our goal accrue 59 patient receive autologous vaccine individual lymphoma undergo stem cell transplantation . Our hope vaccination prolong time patient stay remission disease .</brief_summary>
	<brief_title>Phase 1-2 CpG-Activated Whole Cell Vaccine Followed Autologous Immunotransplant MCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Inclusion Criteria ( time enrollment ) : Patients must newly diagnose mantle cell lymphoma , accessible disease site excisional biopsy sufficient peripheral blood tumor leukapherese least 1.5 x 109 lymphoma cell single session . By standard clinical criterion , medically appropriate receive rituximab standard induction chemotherapy highdose chemotherapy AHCT . Patients must HIV negative . ECOG performance status 0 , 1 , 2 Karnofsky performance scale 50100 % . Patients must capable signing informed consent . Patients currently take immunosuppressive medication . Patients severe psychological medical illness . Pregnant lactating woman . At discretion principal investigator he/she feel patient unable safely complete study . Specifically , patient must consider medically eligible undergo standard high dose chemotherapy autologous stem cell transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>